Issue 005 | August 2026 | Free to read |
The Skill Bridge: How to Get From Where You Are to Where Pharma AI Is Going
Two entry points. Two skill-build paths. One destination. Startups, CDMOs, and big pharma — where each profile fits best. Plus the trends defining what to learn next.
By the numbers
78% Execs recruiting for bio + AI hybrid roles | +178% AI skill demand in CDMO sector 2023-25 | 40%+ AI life sciences jobs growth next 5 yrs (WEF) | 64% Biopharma orgs actively recruiting |
Sources: Deloitte 2026 AI Enterprise Survey, CIEL HR CDMO Report May 2026, WEF Future of Jobs 2025, BioSpace 2026 Employment Outlook
From the editor
A year of watching the biopharma AI hiring market up close has taught me one thing clearly: the bottleneck is not investment, not compute, and not ambition. It is people who can operate across the whole stack.
Big pharma is hiring at scale. The job postings are real, the budgets are approved, and the urgency is genuine. But the profiles that organisations actually need — someone who can sit in a regulatory strategy meeting in the morning, define an AI validation framework in the afternoon, and review a model deployment pipeline before close of business — simply do not exist in sufficient numbers. Universities are not producing them. Consulting firms are not producing them. They are being produced, slowly and unevenly, by individuals who decided to build the bridge themselves.
That is what this issue is about.
01 | Two Entry Points — One Destination |
Every biopharma AI role can be reached from two starting points. The gaps are different. The build order matters.
A From Biopharma Science Strengths: Domain knowledge, GMP intuition, regulatory literacy, experimental design Starting point: Python fundamentals, R for stats already common in labs Critical gaps: Production ML, cloud infrastructure, software engineering practice First priority: Python data stack (pandas, sklearn, matplotlib) + Jupyter workflow Timeline to hybrid role: 6–12 months with consistent self-study + portfolio project | B From Software / AI Engineering Strengths: ML engineering, cloud deployment, scalable systems, LLMops Starting point: Strong production ML, MLOps, data pipelines already in place Critical gaps: Biology/chemistry domain knowledge, GMP constraints, regulatory context First priority: Molecular biology fundamentals + understanding GxP data governance Timeline to hybrid role: 6–18 months; domain depth takes longer than technical upskilling |
The most successful transitions are adjacent pivots, not complete resets. Leverage what you already know. — CompBioJobs / hire-omics 2026
A | If You Come From Biopharma Science — Build Your Technical Stack |
You have the rarest asset: domain knowledge that takes years to acquire. Now add the technical layer systematically.
Focus | What to build / learn | Specific tools and actions | |
Step 1 | Foundations | Python for biology | Pandas, NumPy, Matplotlib, Jupyter. Apply to your own lab data. RDKit for chemistry. Biopython for sequences. |
Step 2 | Statistics & ML | Statistical learning | scikit-learn core: regression, classification, clustering. Understanding train/test/validate. Cross-validation. Avoid overfitting. |
Step 3 | Domain + ML bridge | Apply to real biology | Predict protein properties (use UniProt data). Build a simple QSAR model. ADMET prediction. Reproduce a published result. |
Step 4 | Deep learning | Neural networks | PyTorch basics. Understand attention mechanism. Fine-tune a pre-trained protein language model (ESM2). Graph neural networks for molecules. |
Step 5 | Cloud & deployment | Production basics | AWS or GCP free tier. S3 for data storage. Basic Docker containerisation. Run a model pipeline end-to-end. |
Step 6 | Portfolio | Demonstrate output | GitHub with documented projects. Reproduce an AlphaFold application. Build a small compound screening pipeline. Write up the biology clearly. |
Table A. Six-step technical build for biopharma scientists. Each step builds on the last. Portfolio projects are non-negotiable — employers hire evidence, not credentials alone.
B | If You Come From Software / AI — Build Your Domain Literacy |
You can build production systems. Now learn what to build them for — and why biology and GMP constraints make it harder than it looks.
Focus | What to learn | Specific resources and actions | |
Step 1 | Biology primer | Core biological literacy | Central dogma, protein structure basics, gene expression, CRISPR concepts. MIT OpenCourseWare 7.01 is free. |
Step 2 | Data fluency | Bioinformatics data types | FASTA, SMILES, SDF, FASTQ, PDB. How sequencing data is processed. What LIMS and ELN data looks like. |
Step 3 | Regulatory context | GxP constraints | 21 CFR Part 11, GMP documentation. Why models must be validated. What audit trail means for ML pipelines. ICH Q10. |
Step 4 | Domain models | Protein / molecule AI | Run AlphaFold2/3 locally. Fine-tune ESM2. Use RDKit for molecule manipulation. Understand why graph neural networks suit molecules. |
Step 5 | Manufacturing AI | Process data context | What PAT data looks like. CPV dashboards. Deviation patterns. Work with public bioprocess datasets (e.g. Roche fed-batch data). |
Step 6 | Collaborate | Find a domain partner | Offer ML skills to a biology/pharma PhD student. Co-author a preprint. Attend ISMB or ASCB. The credibility gap closes with evidence. |
Table B. Six-step domain build for software/AI engineers. The credibility gap closes with evidence of biological understanding, not just technical skills applied to bio data.
02 | Skills Frequency by Domain |
Which skills appear most in job descriptions — by domain. Plan your build accordingly.
Skill | Drug Discovery | Clinical Dev | CMC / Mfg | PV / Reg |
Python | 98% | 82% | 75% | 70% |
PyTorch / TF | 92% | 60% | 40% | 30% |
R / Statistics | 65% | 90% | 85% | 80% |
GMP / Regulatory | 15% | 35% | 90% | 85% |
Cloud AWS/GCP | 72% | 65% | 60% | 55% |
NLP / LLMs | 60% | 55% | 45% | 88% |
Process data/PAT | 8% | 10% | 85% | 20% |
Bioinformatics/NGS | 88% | 50% | 20% | 15% |
AlphaFold/Struct | 80% | 30% | 15% | 10% |
SQL / Data eng. | 55% | 70% | 80% | 75% |
Table 1. Skill demand heat map. Bar length = frequency in 500+ active postings. GMP/regulatory knowledge is the sharpest differentiator between discovery and CMC roles.
03 | Role Match — Skills to Destination |
Which role fits which background, what skills to prioritise, and where each role is most actively posted.
Role | Background fit | Key technical skills | Where to find the role | Demand signal |
Computational Biologist | PhD Bio/Chem + Python basics | Protein LMs, multi-omics, AlphaFold | Big pharma R&D, AI-native biotechs (Recursion, Insilico) | Strong — deep domain + growing ML |
ML Engineer (Drug Discovery) | Strong ML + bio literacy | PyTorch, JAX, generative models, GNNs | AI-native startups (Isomorphic, Chai, Exscientia) | Very high — rarest profile |
CMC Data Scientist | MS/PhD Chem. Eng. + Python | JMP, PAT data, SQL, process ML | Large pharma CMC (Lilly, Moderna), CDMOs | Growing fast — biggest gap vs supply |
PV AI Analyst | Life sci degree + NLP skills | NLP/LLMs, SQL, Argus/Veeva | Pharma PV teams, CROs (IQVIA, ICON) | High demand — lower entry barrier |
Regulatory AI Specialist | Pharma/RA background + NLP | NLP, ICH M14, eCTD tools, Python | Regulatory affairs teams, consultancies | Emerging — very few with both skills |
RWE Data Scientist | Epidemiology/Stats + data engineering | R, Python, SAS, RWD platforms | Medical affairs, HEOR teams, CROs | Consistent demand — post-approval focus |
Bioinformatics Scientist | CS/Math + bio domain | Nextflow, R, cloud, single-cell | Genomics-focused biotechs, CROs, academic spinouts | Stable — evolving toward AI integration |
Table 2. Role match by background and skill profile. CMC Data Scientist has the largest supply gap relative to demand in 2026. ML Engineer (Drug Discovery) has the highest comp ceiling.
04 | Where to Apply — Startup, Big Pharma, CDMO, CRO, Biotech |
Each org type values a different profile mix. Know where your skill combination fits before you apply.
Org type | Examples | Skills prioritised | What to know |
AI-Native Startup | Isomorphic, Recursion, Chai, Insilico, Exscientia, BenevolentAI | Production ML, generative models, agentic AI, MLOps, protein LMs | Highest comp + equity, least structure. Biology literacy a plus. Move fast, build everything. |
Big Pharma R&D | Lilly, Genentech, Pfizer, AZ, Takeda, Novartis, GSK, BMS | ML + domain depth, regulatory awareness, GxP data literacy, cross-functional comms | Structured hiring. PhD expected senior levels. Platform deals (Chai, Noetik, Boltz) mean roles focus on integration. |
CDMO | Lonza, Samsung Bio, Wuxi, Catalent, Thermo Fisher, Fujifilm Diosynth | Process AI, PAT data, quality automation, eBR, LIMS/MES integration | AI demand up 178% in 2 yrs (CIEL HR). Hybrid process + ML profiles in very short supply. |
CRO / Service Org | IQVIA, Parexel, ICON, Syneos, Labcorp, Accenture Life Sciences | NLP for PV, RWE analytics, clinical AI, SQL, Argus/Veeva, Python | Largest PV AI hiring pool. Lower entry bar. Good entry point for biology-to-AI transition. |
Biotech (Series A-C) | CGT, rare disease, and platform biotechs | Comp bio + bioinformatics + data engineering. Scrappy, autonomous delivery | Often first AI/data hire. High ownership. Equity significant. Biology depth valued over ML depth at early stage. |
Table 3. Organisation type comparison. CDMO sector: AI skill demand up 178% in 2 years (CIEL HR, May 2026). India expected to add 45,000-60,000 CDMO roles by 2028-29.
05 | Future Trends — What to Learn Next and Why |
Seven emerging capability areas with market signals and specific skills to start building now.
Emerging trend | Horizon | Skill to develop now | Market signal |
Agentic AI in R&D | 1-2 yrs | LLM orchestration, tool-calling APIs, RAG pipelines, evaluation frameworks | 3x increase in 'AI agents' job descriptions H1 2026 vs H1 2025. Genentech ML Agents for Science role is the blueprint. |
Foundation models for biology | 2-3 yrs | Protein LMs (ESM3, AlphaFold3), DNA LMs (Nucleotide Transformer), multi-modal bio-AI | Lilly/Chai, GSK/Noetik — platform access deals signal that specialised foundation models are the infrastructure layer. |
Manufacturing digital twin | 2-4 yrs | Process simulation, real-time data integration, ML control loops, OPC-UA, edge computing | ICH Q13 continuous manufacturing + AI PAT convergence. CDMOs building digital twin capability as differentiator. |
AI-native CMC submissions | 3-5 yrs | CDISC/IDMP fluency, ML model validation for regulatory, AI credibility assessment (FDA 7-step framework) | FDA Q2 2026 guidance finalisation. BLA sections with AI-assisted process descriptions becoming realistic. First movers building now. |
Real-time PV / continuous surveillance | 2-4 yrs | Streaming data pipelines, NLP at scale, ICH M14 study design, signal detection algorithms | ICH M14 (March 2026) + EMA reflection paper mandate infrastructure. PV AI roles growing at fastest index rate of any domain. |
AI for personalised dosing | 4-7 yrs | PK/PD modelling, connected device data, federated learning, clinical decision support AI | MedTech-pharma convergence. CGM + GLP-1 drugs as early model. Regulatory pathway for adaptive dosing AI still developing. |
Multi-modal drug design | 3-6 yrs | Integration of structural, genomic, proteomic, and clinical data into unified models; JAX, SE(3) equivariant nets | Isomorphic Labs approach. Current limitation is data availability and model generalisation across modalities. |
Table 4. Emerging capability areas by time horizon. Horizon = when the skill becomes mainstream hiring requirement, not when the technology first appears. Start building 2 years before the horizon.
The three things that actually differentiate hybrid profiles 1. Evidence of cross-domain delivery — a GitHub project, a preprint, a deployed tool that touches both biology and ML. 2. Regulatory literacy — understanding why GMP data governance and model validation requirements exist, not just knowing they do. 3. Communication across the divide — being able to explain ML to a biologist and biology to an ML engineer. The rarest skill of all. |
The Intelligent Pipeline Practitioner-grade, vendor-neutral insight for biopharmaceutical scientists and CMC leaders. If this was useful, forward it to one colleague who would appreciate it. | Published by CellCraft AI LLC Not AI-generated. AI-assisted writing tools used for structural review and drafting support only. All analysis and industry perspective are human-authored. |